Can low‑dose naltrexone (LDN) help reduce scalp itching?

Low-Dose Naltrexone for Scalp Itching

Low-dose naltrexone (LDN) at 1–5 mg daily can effectively reduce scalp itching, particularly when associated with inflammatory scalp conditions such as lichen planopilaris, and may also help with pruritus of unknown origin. 1, 2

Mechanism and Evidence Base

LDN works through multiple anti-inflammatory pathways that directly address itch:

• Transiently blocks opioid receptors, leading to increased receptor expression that favors κ over μ receptors, which decreases inflammatory mediators and reduces itch sensation. 1
• Antagonizes toll-like receptor 4 (TLR-4), a pro-inflammatory pathway, providing additional anti-inflammatory effects beyond opioid receptor modulation. 1
• These combined mechanisms make LDN particularly effective for inflammatory and autoimmune-mediated pruritus. 3

Clinical Evidence for Scalp Conditions

Lichen Planopilaris (LPP)

• A prospective study of 26 patients using 3 mg daily LDN showed significant reduction in scalp erythema at 12 months (mean decrease of 0.93 on a 0–3 scale, p<0.0001), with trends toward decreased scale. 4
• A retrospective case series of 4 LPP patients demonstrated reduction in pruritus, clinical inflammation, and disease progression with 3 mg daily LDN, with all patients tolerating the medication without adverse effects. 2
• LDN appears most effective when prominent erythema is present on the scalp. 4

General Pruritus

• A systematic review found naltrexone (both low and standard doses) effective in treating pruritus from multiple causes including atopic dermatitis, prurigo nodularis, cholestasis, burn injury, systemic sclerosis, and Hailey-Hailey disease. 3
• Low-dose formulations (1.5–4 mg daily) demonstrated fewer adverse effects compared to standard doses (50–100 mg) while maintaining efficacy. 3

Guideline Context

While British Association of Dermatologists guidelines recommend standard-dose naltrexone for generalized pruritus of unknown origin (Strength D), they do not specifically address low-dose formulations. 5 However, the guidelines do support naltrexone as a systemic option when topical measures and antihistamines fail. 5

For opioid-induced pruritus, guidelines recommend naltrexone at 6–9 mg doses, though this risks reducing analgesia. 5 This is distinct from the inflammatory pruritus LDN targets.

Practical Prescribing

Dosing

• Start with 1.5–3 mg daily, typically compounded by a specialty pharmacy. 1, 2
• Maximum studied dose is 5 mg daily for dermatologic conditions. 1
• The 3 mg daily dose has the most robust evidence for scalp conditions. 4, 2

Safety Considerations

• Patients must be opioid-free for 7–10 days before starting naltrexone to avoid precipitating withdrawal; those transitioning from buprenorphine or methadone may require up to 2 weeks. 6
• Monitor liver function, particularly in patients with pre-existing hepatic impairment, as naltrexone bioavailability increases 5–10 fold in cirrhosis. 6
• LDN is generally well-tolerated with minimal side effects compared to standard naltrexone doses. 1, 3
• Patients on LDN will not respond to opioid analgesics and should carry identification indicating naltrexone use. 6

Access Barriers

• LDN typically requires compounding by a specialty pharmacy, which may pose cost and access challenges. 1
• This is not an FDA-approved indication; standard naltrexone is approved only for alcohol and opioid dependence. 6

Clinical Algorithm

For scalp itching with visible inflammation (erythema, scale):

1. Consider LDN 3 mg daily as adjunctive therapy, particularly if lichen planopilaris or other inflammatory scalp condition is suspected. 4, 2
2. Expect gradual improvement over 6–12 months; erythema typically responds before other symptoms. 4

For scalp itching without clear inflammatory signs:

1. First pursue guideline-directed workup and topical management (emollients, menthol, low-potency corticosteroids). 5, 7
2. If topical measures and non-sedating antihistamines fail, consider LDN as a systemic option alongside other agents like gabapentin or mirtazapine. 5, 1

Critical Pitfalls

• Do not prescribe LDN to patients currently using opioids or those who have used opioids within the past 7–10 days, as this will precipitate severe withdrawal. 6
• Do not assume immediate relief; clinical response to LDN typically requires several months of continuous therapy. 4
• Do not overlook hepatic function monitoring, especially in patients with known liver disease. 6
• Ensure patients understand they cannot use opioid pain medications while on naltrexone and should carry identification. 6